Piomic has developed a technology that uses electromagnetic pulses to improve wound healing. Because the therapy helps accelerate wound healing, it is ideal for the treatment of chronic wounds.
The technology produced encouraging results in its first clinical trial. Now, the company has impressed existing business angels and further private investors enough to successfully close a seed financing round, announced a statement.
Piomic plans to use the proceeds of the undisclosed investment to accelerate the development of its advanced wound care product and expand its team. With more than 50 million patients worldwide affected by chronic wounds, the company aims to provide clinical and economic benefits to institutions treating non-healing wounds.
“The continuous positive feedback of patients and physicians is a positive endorsement of Piomic´s therapeutic approach,” commented Christopher Hertz, co-founder and CEO of Piomic.
More News
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space